Synonym: 1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride; JM3100; Plerixafor; SID791
CAS Number: 155148-31-5 (anhydrous)
Empirical Formula (Hill Notation): C28H54N8 · 8HCl · xH2O
Molecular Weight: 794.47 (anhydrous basis)
Linear Formula: C28H54N8 · 8HCl · xH2O
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: A5602-5MG
assay |
≥97% (NMR) |
form |
solid |
InChI |
1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2 |
InChI key |
GKFHDCZYJHUPEN-UHFFFAOYSA-N |
originator |
Sanofi Aventis |
Quality Level |
100 |
SMILES string |
Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2 |
solubility |
H2O: ≥10 mg/mL, clear |
storage condition |
desiccated |
storage temp. |
−20°C |
Application: |
AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases. |
Biochem/physiol Actions: |
AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. |
Features and Benefits: |
This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: |
5 mg in glass bottle |
RIDADR |
NONH for all modes of transport |
WGK Germany |
WGK 3 |
Flash Point(F) |
Not applicable |
Flash Point(C) |
Not applicable |
Purity |
≥97% (NMR) |
Storage Temp. |
−20°C |
UNSPSC |
51111800 |